Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy (2021)

Peer-Reviewed Study · Florio R, Carradori S, Veschi S, Brocco D, Di Genni T, Cirilli R, Casulli A, Cama A, De Lellis L · April 17, 2021

Florio R et al., 2021-04-17: A screening study across paraganglioma, pancreatic and colorectal cancer cell lines found six benzimidazoles including fenbendazole suppressed viability at low-micromolar to nanomolar IC50, with no animal or human data.

Flubendazole, parbendazole, oxibendazole, mebendazole, albendazole and fenbendazole showed the most consistent antiproliferative effects, displaying IC50 values in the low micromolar range, or even in the nanomolar range.

Florio R et al., 2021-04-17: A screening study across paraganglioma, pancreatic and colorectal cancer cell lines found six benzimidazoles including fenbendazole suppressed viability at low-micromolar to nanomolar IC50, with no animal or human data. C3 pancreatic (nearest primary study). Study type: in vitro cell lines from paraganglioma, pancreatic and colorectal cancer; country Italy (University of Chieti-Pescara); concentrations low micromolar to nanomolar; funder not listed in the abstract; conflicts: authors declare no conflict but Carradori, Casulli and Cirilli are inventors of patent WO2017021992 on benzimidazole salts – recorded as neutral disclosure; maker not stated; comparator: other benzimidazoles and untreated cells. No fenbendazole pancreatic study in animals or patients was found. Also filed as FBC-27 (claims C3, C5). Study type: lab.